AlphAIAlphAI — Financial news for AI agents
stocktitan.net$MNKD

A 4:30 p.m. ET call on Nov. 5 will cover MannKind’s results and business update.

MannKind (MNKD) will release Q3 2026 earnings after market close on Nov. 5, followed by a conference call at 4:30 p.m. ET. The call will discuss financial results and provide a business update. The webcast will be available on the company's Investor Relations website.

Original reporting
stocktitan.net
Published Oct 29, 2026, 8:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 8:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$MNKD
Neutral
medium confidence
Mentioned
$MNKD
Relevance
4/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$MNKDNeutralLow
01

Why it matters

The call announcement itself does not change fundamentals but informs traders of the timing for potential price moves tied to the upcoming earnings release.

02

Market read

Low immediate relevance; primarily a scheduling notice for the Q3 2026 earnings release.

03

What to watch

Analyst expectations and prior quarter performance may already be priced in, reducing the impact of the call notice.

Relevance 4/10Novelty 3/10Timing: pre-market on Nov 5

Background

MannKind is a Nasdaq‑listed biopharma focused on cardiometabolic and orphan lung diseases. The company routinely schedules earnings calls to discuss quarterly results.

Company-level read

Ticker impact

$MNKDNeutralMedium confidence
Context

MannKind announced the date and time of its Q3 2026 earnings call and webcast.

Expected impact

possible modest volatility around the November 5 results as traders position for the earnings surprise.

Evidence & confidence

No new financial data is disclosed; the news is a standard earnings call notice.

Market effects

Sector

None beyond the biotech/biopharma sector awareness of upcoming results.

Regional

Limited to U.S. investors tracking small-cap biotech stocks.

Global

Minimal.

Counterpoint

What could challenge this read

If the market overreacts to the call announcement, a short position could be considered ahead of the earnings release.

Key entities

  • company
    MannKind Corporation

    Nasdaq‑listed biopharmaceutical company (ticker MNKD).

Read at source← All news

Related articles

$MNKDMed

MannKind (MNKD) Q3 2026 Earnings Call Transcript

MannKind (MNKD) reported Q3 2026 revenue of $101.9M, up 24% YoY. Furoscix ReadyFlow approval drove strong adoption, with 75% of prescriptions converted. Afrezza pediatric launch exceeded forecasts, with total prescriptions up 17% sequentially. The company anticipates $15M in milestones from ralinepag DPI in 2027 and key clinical data for nintedanib DPI in early 2028. MannKind closed a $50M private placement, funding a $45M CVR payment.

finance.yahoo.com
$MNKDMed

Cantor Fitzgerald raises MannKind stock price target to $10 on Tyvaso momentum

Cantor Fitzgerald raised its price target for MannKind Corp. (NASDAQ:MNKD) to $10.00, citing momentum for Tyvaso DPI and a delayed competitor. The firm expects profitability in 2026, with revenue growth of 30% and a 75% gross margin. MannKind reported Q3 2026 revenue of $101.9M, missing estimates but showing a smaller loss than expected. The company's commercial products and royalties drove growth.

investing.com
$MNKDHigh

MannKind Reports Third Quarter 2026 Financial Results and Provides Business Update

MANNKIND CORP (MNKD) filed an SEC Form 8-K — Results of Operations and Financial Condition. MannKind Reports Third Quarter 2026 Financial Results and Provides Business Update • Q3 2026 total revenues of $101.9 million, +24% vs. Q3 2025 • Q3 2026 commercial product revenue of $45.0 million, +102% vs. Q3 2025 o Furoscix ReadyFlow ™ was approved and shipments commenced mid

SEC EDGAR 8-K
$MNKDMedAI 8/10

A heart-failure injector delivers a full dose in under 10 seconds. Urine output was similar to treatment into a vein.

MannKind (MNKD) presented clinical data at HFSA 2026 showing Furoscix ReadyFlow's comparable urine output to IV furosemide. The autoinjector delivers an 80 mg/mL dose in under 10 seconds, with 91.3% and 92.7% bioavailability in thigh and upper-arm injections, respectively. ReadyFlow received FDA approval in July 2026 for fluid overload treatment in heart failure or CKD patients.

stocktitan.net